These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Escalating MS drug costs in the US: Puzzling, troubling, and suspicious. Murray TJ; Brown MG Neurology; 2015 May; 84(21):2105-6. PubMed ID: 25911109 [No Abstract] [Full Text] [Related]
65. The mood-immunity relationship in multiple sclerosis. Ristori G; Annibali V; Salvetti M Exp Neurol; 2013 Mar; 241():34-7. PubMed ID: 23219886 [No Abstract] [Full Text] [Related]
66. Tumor Necrosis Factor α Blockers and the Risk of Multiple Sclerosis. Strijbis EMM; Koch MW Neurology; 2023 Feb; 100(6):267-268. PubMed ID: 36307218 [No Abstract] [Full Text] [Related]
67. Proceedings of the 12th International TNF Conference, 2009. Adv Exp Med Biol; 2011; 691():v-xxxvi, 1-844. PubMed ID: 21491779 [No Abstract] [Full Text] [Related]
68. Small-molecule inhibitors get pro-inflammatory TNF into shape. Savvides SN; Elewaut D Nat Rev Rheumatol; 2020 Apr; 16(4):189-190. PubMed ID: 32060426 [No Abstract] [Full Text] [Related]
69. Practical management of patients on anti-TNF therapy - the CRI guidelines. Sellam J; Morel J; Tournadre A; Pham T; Richez C; Joint Bone Spine; 2021 May; 88(2 Suppl 1):105173. PubMed ID: 33992226 [No Abstract] [Full Text] [Related]
70. Common sense paths follow brain injuries. Jacobson S J Neuroimmune Pharmacol; 2012 Dec; 7(4):717-8. PubMed ID: 23138697 [No Abstract] [Full Text] [Related]
72. [ON THE PLANNING OF THERAPEUTIC TRIALS IN MULTIPLE SCLEROSIS]. WELTE E Methods Inf Med; 1963 Jul; 2(3):95-100. PubMed ID: 14045640 [No Abstract] [Full Text] [Related]
73. Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure. Yu AW; Pecsok M; Longbrake EE; Wesley SF Neurol Clin Pract; 2021 Aug; 11(4):e488-e496. PubMed ID: 34484946 [TBL] [Abstract][Full Text] [Related]
74. Pathological findings in central nervous system demyelination associated with infliximab. Kalinowska-Lyszczarz A; Fereidan-Esfahani M; Guo Y; Lucchinetti CF; Tobin WO Mult Scler; 2020 Aug; 26(9):1124-1129. PubMed ID: 31845616 [TBL] [Abstract][Full Text] [Related]
76. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Calza L; Fernandez M; Giuliani A; Aloe L; Giardino L Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3258-63. PubMed ID: 11867745 [TBL] [Abstract][Full Text] [Related]
77. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Hohlfeld R Mult Scler; 1996 Jul; 1(6):376-8. PubMed ID: 9345421 [TBL] [Abstract][Full Text] [Related]
78. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Taoufik E; Tseveleki V; Chu SY; Tselios T; Karin M; Lassmann H; Szymkowski DE; Probert L Brain; 2011 Sep; 134(Pt 9):2722-35. PubMed ID: 21908876 [TBL] [Abstract][Full Text] [Related]